The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Georg LenzDuring the 17th ICML, the Lymphoma Hub spoke with Georg Lenz, Münster University Hospital, Münster, DE. We asked for a summary of Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone) vs R-CHOEP (cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and etoposide) treatment in young patients with high-risk diffuse large B-cell lymphoma (DLBCL). Lenz highlights the efficacy and safety data of each treatment for this population of patients.
Pola-R-CHP vs R-CHOEP in young patients with high-risk DLBCL